Intellia Therapeutics (NTLA)

• Market cap: $1.24B
• 1 day: -0.65%
• 5 days: 23.43%
• 1 month: 22.43%
• 3 months: -11.81%
• 6 months: -48.45%
• Year to date: -0.41%
• 1 year: -54.72%
• 5 years: -9.11%
• 10 years: -44.93%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

About: Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Employees: 598

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

94% more repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 65

43% more call options, than puts

Call options by funds: $16.5M | Put options by funds: $11.5M

33% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 49

5.09% more ownership

Funds ownership: 92.38% [Q3] → 97.47% (+5.09%) [Q4]

4% more funds holding

Funds holding: 279 [Q3] → 289 (+10) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

39% less capital invested

Capital invested by funds: $1.93B [Q3] → $1.17B (-$758M) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $11 10% downside
• Avg. target: $35 184% upside
• High target: $60 393% upside

5 analyst ratings

• positive: 3 60%
• neutral: 2 40%
• negative: 0 0%

Morgan Stanley Terence Flynn 50% 1-year accuracy 9 / 18 met price target	10% downside $11	Equal-Weight Downgraded	27 Jan 2025
Goldman Sachs Salveen Richter 27% 1-year accuracy 4 / 15 met price target	1% downside $12	Neutral Maintained	14 Jan 2025
Oppenheimer Jay Olson 23% 1-year accuracy 23 / 101 met price target	229% upside $40	Outperform Maintained	13 Jan 2025
BMO Capital Kostas Biliouris 25% 1-year accuracy 5 / 20 met price target	311% upside $50	Outperform Maintained	10 Jan 2025
Wells Fargo Yanan Zhu 7% 1-year accuracy 1 / 15 met price target	393% upside $60	Overweight Maintained	10 Jan 2025